Sanofi (NASDAQ:SNY) has executed the first tranche of its €5 billion stock buyback program. A first tranche of this program was announced on February 3, 2025, and executed on February 5, 2025, for an ...

Sanofi (SNY), a French pharmaceutical and healthcare company, Friday announced that it is executing the second tranche of its share ...

French pharmaceutical and healthcare company Sanofi on Friday announced a share buyback plan worth up to €2 billion ($2.08 billion), to be completed between now and the end of December 2025. Sanofi ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to ...

Execution of a share buyback agreement for up to €2 billionParis, February 7, 2025. On January 30, 2025, Sanofi announced its intention to ...

Sanofi said the acquisition of these shares ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 ( Sanofi ...